Drugs / MK-4700
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06894771 | Apr → Dec 2025 | cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4700 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06894771 ↗ |
| Route | Subcutaneous | “Administered via subcutaneous (SC) injection” NCT06894771 ↗ |